EUVIMEDEUVIMED entdecken
Crossref

Design and synthesis of pyrrolo[2,3-d]pyrimidine linked diazospiro and piperazine – piperidine libraries as anticancer agents

Sridhar Guda, Srilakshmi V Patri iD, Krishna Reddy V, Vishnu Thumma, Santosh Kumar Guru

Medicinal Chemistry Research · 2026-08 · 35 (8) · 1515-1528

DOI: 10.1007/s00044-026-03596-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinal Chemistry Research, online erschienen am 17.07.2026. Verfasst von Sridhar Guda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, National Institute of Technology, Warangal, 5060004, Telangana, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyrimidines, Piperidines, Pyrroles. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Scheme for Promotion of Academic and Research Collaboration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three libraries containing pyrrolo[2,3-d]pyrimidine moiety linked to diazospiro[3.5]nonane, diazospiro[5.5]undecane and piperazine - piperidine hybrid derivatives were synthesized involving various N-deprotection and acid amine coupling reactions. They were tested for their invitro cytotoxicity against triple negative human breast cancer cells MDA-MB-231 and BT-549. Promising results were obtained by pyrrolo[2,3-d]pyrimidine linked diazospiro[3.3]nonane compounds (7a and 7c) containing ortho-trifluoro and meta-bromo functional groups against MDA-MB-231 cells. Their dose response curves were plotted and their IC50 value found to be 11.66 µM (7a) and 10.37 µM (7b). Additionally, performed acridine orange and rhodamine 123 straining tests to study the cell deformation at various dosages, which garnered promising results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPyrimidinesPiperidinesPyrrolesDrug DesignPiperazinesSpiro CompoundsSmall Molecule LibrariesHumansDrug Screening Assays, AntitumorStructure-Activity RelationshipCell Line, TumorCell ProliferationPiperazineMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

Acridine orange strainingCytotoxicityDiazospiro[3.3]nonaneDiazospiro[5.5]undecanePyrrolo[2,3-d]pyrimidineRhodamine 123 straining

Substanzen

Antineoplastic AgentsPyrimidinesPiperidinesPyrrolesPiperazinesPiperazinepiperidineSpiro CompoundsSmall Molecule Libraries

Autor:innen und Institutionen

  • Department of Chemistry, National Institute of Technology, Warangal, 5060004, Telangana, India.
  • Medicinal Chemistry Laboratory Division, Aragen Life Sciences Pvt Ltd, IDA Mallapur, Hyderabad, 500076, Telangana, India.
  • Department of Chemistry, National Institute of Technology, Warangal, 5060004, Telangana, India. patrisrilakshmi@nitw.ac.in.
  • Department of Sciences and Humanities, Matrusri Engineering College, Hyderabad, 500059, Telangana, India.
  • National Institutes of Pharmaceutical Education and Research, Hyderabad, 500037, Telangana, India.

ORCID-Profile: Srilakshmi V Patri

Förderung

  • Scheme for Promotion of Academic and Research Collaboration

Zitieren

APA

Guda, S., Patri, S. V., Reddy V, K., Thumma, V., & Guru, S. K. (2026). Design and synthesis of pyrrolo[2,3-d]pyrimidine linked diazospiro and piperazine – piperidine libraries as anticancer agents. Medicinal Chemistry Research, 35(8), 1515-1528. https://doi.org/10.1007/s00044-026-03596-5

Vancouver

Guda S, Patri SV, Reddy V K, Thumma V, Guru SK. Design and synthesis of pyrrolo[2,3-d]pyrimidine linked diazospiro and piperazine – piperidine libraries as anticancer agents. Medicinal Chemistry Research. 2026;35(8):1515-1528. doi:10.1007/s00044-026-03596-5

BibTeX
@article{Guda2026,
  author = {Guda, Sridhar and Patri, Srilakshmi V and Reddy V, Krishna and Thumma, Vishnu and Guru, Santosh Kumar},
  title = {Design and synthesis of pyrrolo[2,3-d]pyrimidine linked diazospiro and piperazine – piperidine libraries as anticancer agents},
  journal = {Medicinal Chemistry Research},
  year = {2026},
  volume = {35},
  number = {8},
  pages = {1515--1528},
  doi = {10.1007/s00044-026-03596-5}
}
Kostenlos starten →